We scan new podcasts and send you the top 5 insights daily.
Clinicians consider PARP re-challenge primarily when progression occurs after a prolonged period off maintenance rather than during active therapy. Due to regulatory shifts and emerging practice patterns, repeat treatment is reserved for BRCA-mutated patients with preserved platinum sensitivity.
Retrospective data from the PAOLA-one trial shows a significant reduction in benefit from subsequent platinum-based therapy for patients who progressed while on a PARP inhibitor. Objective response rates dropped from 50-60% (placebo group) to 30% (PARP group).
The traditional six-month timeframe for defining platinum sensitivity is being challenged. A growing theory suggests that tumors progressing while on a PARP inhibitor have a distinct biology that responds poorly to subsequent platinum, indicating a potential need to move directly to therapies like ADCs.
The traditional definition of platinum-resistant ovarian cancer based on a six-month recurrence interval is becoming less rigid. Clinicians recognize this timeframe can be an arbitrary surrogate for tumor biology, influenced by imaging schedules. The paradigm is shifting, especially post-PARP inhibitor therapy, where the value of re-challenging with platinum is being reconsidered despite shorter intervals.
The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.
The widespread use of PARP inhibitors has altered tumor biology in platinum-sensitive ovarian cancer. A recent meta-analysis of heavily pretreated patients, 97% of whom had prior PARP inhibitor exposure, revealed an objective response rate to subsequent therapy of only 17%—far lower than historical expectations, highlighting a critical unmet clinical need.
When a patient has a BRCA2 mutation, clinicians on the panel view it as such a dominant predictive biomarker that they would prioritize a PARP inhibitor-based triplet regimen. This single genetic finding often outweighs other clinical factors or even the potential addition of docetaxel in treatment decisions.
While retreating with a PARP inhibitor after a long progression-free interval is a viable strategy for patients with BRCA mutations, experts express caution and hesitancy in applying the same approach to patients who are HRD-deficient but BRCA wild-type, partly due to changing FDA labels.
A nuanced approach to PARP inhibitors involves reserving combinations for BRCA2 patients with clear, aggressive clinical features like high-volume disease or liver metastases. This strategy balances potent efficacy against toxicity for a molecularly defined but clinically heterogeneous group, avoiding overtreatment of those with more indolent disease.
The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.
Experts advise using PARP inhibitors at the earliest opportunity for patients with BRCA mutations. As prostate cancer advances, it develops additional drivers of disease and intrinsic resistance, which can render targeted therapies like PARP inhibitors less effective if they are reserved for later lines of treatment.